Quantcast
Last updated on April 24, 2014 at 14:12 EDT

Latest Cannabidiol Stories

2014-04-07 12:34:01

International Exclusive Partnership Brings Significant Scientific Advantage MARKHAM, ON, April 7, 2014 /CNW/ - MedReleaf(TM), a licensed producer and supplier of medical cannabis, is tapping into its exclusive partnership with world-class leader Tikun Olam(TM), to bring Canadians an offering of medical cannabis varieties unmatched by any other producer licensed through Health Canada's Marihuana for Medical Purposes Regulations. Tikun Olam is the first and largest...

2014-02-13 12:28:05

VANCOUVER, Feb. 13, 2014 /CNW/ - MediJean, a medical marijuana company who has been given approval by Health Canada to grow medical cannabis for R&D purposes, today provided insight into the research they are working on that will help patients and doctors better understand this medicine. "The R&D we are conducting on medical marijuana is groundbreaking," said Charles Scott, director of research and development at MediJean. "Many believe that 'CBD' levels are the sole...

2013-12-31 23:22:55

In a new post on The Compassion Chronicles, “Cannabinoids, Illinois’ Adams and Discovering Cannabidiol,” author Bryan W. Brickner celebrates the work of chemist Roger Adams of the University of Illinois (Champaign-Urbana), his 1940 discovery of the herbal cannabinoid Cannabidiol, as well as Illinois’ Medical Cannabis Pilot Program beginning January 1. Chicago, IL (PRWEB) December 31, 2013 “Roger Adams is associated with the University of Illinois and its heritage,” noted Bryan...

2013-12-11 04:21:11

LONDON, Dec. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma. Glioma...

2013-11-19 04:22:53

- Conference Call Today at 8:00 a.m. ET, 1:00 p.m. GMT - LONDON, Nov. 19, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces its preliminary results for the fourth quarter and the year ended 30 September 2013. 2013 HIGHLIGHTS: -- Initial public offering on the NASDAQ...

2013-11-05 08:35:49

SASKATOON, Nov. 5, 2013 /CNW/ - CanniMed Ltd., the first producer to have received a license under the new Marihuana for Medical Purposes Regulations (MMPR), released their first shipment of medical marijuana to Canadian patients. "Since receiving our license on September 19th, our team has been working tirelessly to ensure that patients receive their trusted medication as early as possible," said Brent Zettl, CEO, CanniMed Ltd. "Continuity of care is critical for patients and...

Marijuana May One Day Help Treat MS Symptoms
2013-10-08 05:11:16

April Flowers for redOrbit.com - Your Universe Online Multiple Sclerosis, an inflammatory disease in which the immune system attacks the nervous system, results in a wide range of debilitating motor, physical and mental problems. Scientists still have no idea why someone gets the disease or how to treat it. A new study, led by Tel Aviv University's Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases and Sackler Faculty of Medicine, reveals some of the chemical...

2013-10-02 08:29:56

- New data reinforces the efficacy and safety profile of Sativex® in Multiple Sclerosis Spasticity - LONDON, Oct. 2, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced that data from new MS spasticity studies (clinical trial data, observational study data and registries data collection) is being presented today at the 29(th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. The...

2013-09-23 08:27:51

LONDON, Sept. 23, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that agreement for a revised mutually-acceptable reimbursement price for Sativex® has been reached between Almirall S.A., GW's commercial partner in Germany, and the German National Association of Statutory Health Insurance Funds (GKV-SV). This new agreement has resulted in an increase to the previously reduced price imposed by the German authorities in March 2013 which...

2013-09-18 04:22:35

LONDON, Sept. 18, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy. Over the last five years, GW has conducted an extensive pre-clinical cannabinoid research program in the field of epilepsy in collaboration with the University of Reading in the United Kingdom. This research has led to the emergence of a number of promising cannabinoid...